» Articles » PMID: 11672906

Identification of an Association Between HLA Class II Alleles and Low Antibody Levels After Measles Immunization

Overview
Journal Vaccine
Date 2001 Oct 24
PMID 11672906
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

This is the first large cohort study to report a genetic association between humoral antibody level after measles vaccine and the HLA class II genes. The WHO goal to eradicate measles world-wide magnifies the importance of data relating to the influence of immunogenetics on measles vaccine-induced antibody responses. We present here the analysis of 242 individuals who received one dose of measles-mumps-rubella-II (MMR-II) vaccine at the age of 15 months and were genotyped for HLA class II alleles. These subjects fit into one of three categories; 72 were classified as seronegative, 93 were seropositive and 77 were serohyperpositive. HLA-DRB1*03 (odds ratio (OR), 2.22) and HLA-DPA1*0201 (OR, 1.71) were significantly associated with measles vaccine seronegativity, while additional alleles provided suggestive evidence of association with seronegativity: DQA1*0201, DQB1*0201, and DQA1*0501. The alleles DRB1*03 and DQA1*0201 remained statistically significant after accounting for the effects of other alleles. These findings are crucial in designing both measles eradication by the use of vaccine, and future vaccines to be used in genetically heterozygous populations.

Citing Articles

Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population.

Cruz Cisneros M, Anderson E, Hampton B, Parotti B, Sarkar S, Taft-Benz S Vaccines (Basel). 2024; 12(1).

PMID: 38276675 PMC: 10821422. DOI: 10.3390/vaccines12010103.


Vaccinomics: A scoping review.

Dudley M, Gerber J, Budigan Ni H, Blunt M, Holroyd T, Carleton B Vaccine. 2023; 41(14):2357-2367.

PMID: 36803903 PMC: 10065969. DOI: 10.1016/j.vaccine.2023.02.009.


Seroprevalence of diphtheria and measles antibodies and their association with demographics, self-reported immunity, and immunogenetic factors in healthcare workers in Latvia.

Leidere-Reine A, Kolesova O, Kolesovs A, Viksna L Vaccine X. 2022; 10:100149.

PMID: 35243323 PMC: 8881727. DOI: 10.1016/j.jvacx.2022.100149.


A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.

Oyarzun P, Kashyap M, Fica V, Salas-Burgos A, Gonzalez-Galarza F, McCabe A Front Immunol. 2021; 12:598778.

PMID: 33717077 PMC: 7952308. DOI: 10.3389/fimmu.2021.598778.


Precision immunization: a new trend in human vaccination.

Jia S, Li J, Liu Y, Zhu F Hum Vaccin Immunother. 2019; 16(3):513-522.

PMID: 31545124 PMC: 7227635. DOI: 10.1080/21645515.2019.1670123.